You are here

  • Home
  • Archive
  • Volume 9, Issue 10
  • Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

 

Online download statistics by month:

Online download statistics by month: October 2021 to July 2025

AbstractFullPdf
Oct 202111841194369
Nov 2021674675187
Dec 202120920978
Jan 202220921480
Feb 202211811958
Mar 202218618748
Apr 202211711947
May 202212112655
Jun 202214014441
Jul 202210611332
Aug 202214214733
Sep 202212713332
Oct 202210010331
Nov 202216316760
Dec 2022616120
Jan 2023818229
Feb 202310110129
Mar 2023818224
Apr 2023414134
May 2023656628
Jun 2023646420
Jul 2023545426
Aug 2023525219
Sep 2023505014
Oct 202313813829
Nov 202330730718
Dec 202321221231
Jan 2024414218
Feb 2024737328
Mar 2024797971
Apr 2024606138
May 2024545425
Jun 2024575629
Jul 2024858632
Aug 2024646230
Sep 2024424321
Oct 2024858536
Nov 2024909123
Dec 2024969728
Jan 2025969624
Feb 2025717115
Mar 2025808026
Apr 2025868622
May 2025656543
Jun 2025464721
Jul 2025110
Total617462352002